3D Medicines, Inc. is an investing holding company, which focuses on the development and commercialization of immuno-oncology (I/O) therapies with differentiated clinical benefit in response to the trend of treating cancer as a chronic disease. The company was founded by Zhao Long Gong in 2014 and is headquartered in Shanghai, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company